In a myeloma trial, 74% responded to AbbVie’s drug, versus 45.7% on standard therapies.

AbbVie submitted a biologics license application to the FDA for etentamig, a treatment for relapsed or refractory multiple myeloma. The application is based on phase 3 trial data comparing it to standard therapies, according to the company.

AbbVie (ABBV) submitted a Biologics License Application to the FDA for Etentamig to treat relapsed or refractory multiple myeloma. The Phase 3 trial showed a 74% overall response rate, reducing disease progression or death risk by 60%. The FDA will review the application. ABBV stock closed at $286.74, down 0.43% in pre-market trading.

AbbVie (ABBV) submitted a Biologics License Application for etentamig, a treatment for relapsed or refractory multiple myeloma. The submission is based on Phase 3 study results showing a 74.0% overall response rate and a 60% risk reduction in progression-free survival compared to standard therapies. The most common adverse events included cytokine release syndrome and neutropenia.

AbbVie (NYSE: ABBV) submitted a Biologics License Application to the FDA for etentamig, a treatment for relapsed/refractory multiple myeloma. The submission is based on Phase 3 CERVINO study results showing significant improvements in overall response rate (74.0% vs. 45.7%) and progression-free survival (60% risk reduction) compared to standard therapies.

AbbVie's lutikizumab showed significant improvements in hidradenitis suppurativa (HS) patients, meeting primary and secondary endpoints in the phase 3 INTREPID study. At 16 weeks, 31.4% of participants achieved a 75% reduction in lesions vs. 23.4% on placebo. The drug also reduced pain and improved quality of life measures. AbbVie plans FDA submission in 2H 2027.

AbbVie (ABBV) announced FDA approval for at-home subcutaneous induction of Skyrizi for Crohn's disease. The 720mg regimen uses an on-body injector at weeks 0, 2, 4, 8, with maintenance every 8 weeks from week 12. Intravenous induction remains an option.